(Q40698278)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

main subject

Pseudomonas aeruginosa

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Anton Y. Peleg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Carl Kirkpatrick

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Clare C Walsh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Phillip J Bergen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

24 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

3042-3050

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209311%20AND%20SRC:MED&resulttype=core&format=json

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Will new antimicrobials overcome resistance among Gram-negatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Fosfomycin: an old--new antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

The mechanism of action of fosfomycin (phosphonomycin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

21 January 2018

Fosfomycin trometamol

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Fosfomycin: an old, new friend?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Fosfomycin: use beyond urinary tract and gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Antibiotics and the social history of the controlled clinical trial, 1950-1970.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Target site penetration of fosfomycin in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Susceptibility of urinary tract bacteria to fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

In vitro activity of fosfomycin in combination with various antistaphylococcal substances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221

Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV221